Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of AG-348 in Healthy Males
NCT03703505Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoints: AG-348 Excreted Through Urine [A(eu)], AG-348 Excreted through Feces [A(ef)] and 9 more. Started May 2018; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT03703505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703505.